Latest Period
Q2 2026
Security Snapshot
PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) Institutional Ownership
CUSIP: 729139105
13F Institutional Holders and Ownership History from Q2 2020 to Q2 2026
Institutions Reporting
84
Shares (Excl. Options)
48,099,455
Price
$1.14
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- PLRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 48,099,455
- Total 13F value
- $54,832,301
- Portfolio coverage rank
- 0%
- Share change
- -1,580,698
- Value change
- -$2,274,475
- Number of holders
- 84
- Shares outstanding
- 61,907,011
- SEC-reported price per share
- $1.07
- Insider filing price
- $1.07
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PLRX - PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share is tracked under CUSIP 729139105.
- 84 institutions reported positions in Q2 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 89 to 84 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $62,482,903 to $54,832,301.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 84 institutions filings for Q2 2026.
Security key
729139105
Latest holder period
Q2 2026
13F holders
84
13D/G owners
11
CIK / CUSIP context first
Open Q2 2026 holders
PLRX full holder history
PLIANT THERAPEUTICS, INC. SEC filings
PLIANT THERAPEUTICS, INC. company facts
PLIANT THERAPEUTICS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 729139105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
PLRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.6% | $9,198,699 | 5,859,044 | TANG CAPITAL MANAGEMENT, LLC | 03 Mar 2025 | |||
| ADAR1 Capital Management, LLC | 8.9% | $6,281,085 | 5,509,724 | ADAR1 Capital Management, LLC | 30 Jun 2026 | |||
| VANGUARD GROUP INC | 4.9% | $3,482,724 | 3,002,348 | The Vanguard Group | 30 Jun 2025 | |||
| Redmile Group, LLC | 4.8% | $4,545,900 | 2,895,478 | Redmile Group, LLC | 31 Dec 2024 | |||
| CITADEL ADVISORS LLC | 3.5% | -30% | $2,443,506 | -$1,024,526 | 2,143,426 | -30% | Kenneth Griffin | 30 Jun 2026 |
| BlackRock, Inc. | 3.4% | $2,440,674 | 2,104,574 | BlackRock, Inc. | 30 Jun 2025 | |||
| Woodline Partners LP | 3.3% | -57% | $2,471,953 | -$3,023,924 | 2,026,191 | -55% | Woodline Partners LP | 31 Dec 2025 |
| MORGAN STANLEY | 0.9% | -87% | $861,460 | -$5,043,529 | 545,228 | -85% | Morgan Stanley | 31 Dec 2025 |
| FMR LLC | 0.2% | $207,230 | 131,993 | FMR LLC | 28 Feb 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.1% | $137,648 | 87,674 | T. Rowe Price Associates, Inc. | 31 Mar 2025 | |||
| Point72 Asset Management, L.P. | 0.1% | -94% | $56,775 | -$4,926,946 | 46,537 | -99% | Point72 Asset Management, L.P. | 31 Dec 2025 |
As of 30 Jun 2026, 84 institutional investors reported holding 48,099,455 shares of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX). This represents 78% of the company’s total 61,907,011 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
66%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.9% | 6,141,261 | -0.03% | 0.32% | $7,001,038 |
| ADAR1 Capital Management, LLC | 8.9% | 5,509,724 | +113% | 0.3% | $6,281,085 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 2,440,351 | +4.2% | 0% | $2,782,000 |
| ACADIAN ASSET MANAGEMENT LLC | 3.9% | 2,416,508 | 0% | 0% | $2,747,000 |
| TWO SIGMA INVESTMENTS, LP | 3.7% | 2,262,832 | +0.43% | 0% | $2,579,628 |
| CITADEL ADVISORS LLC | 3.5% | 2,142,226 | -34% | 0% | $2,442,138 |
| RENAISSANCE TECHNOLOGIES LLC | 3.3% | 2,049,874 | +11% | 0% | $2,336,856 |
| Monaco Asset Management SAM | 3.1% | 1,938,747 | 0% | 0.82% | $2,210,172 |
| Lynx1 Capital Management LP | 2.9% | 1,798,070 | 0.24% | $2,049,800 | |
| BML Capital Management, LLC | 2.5% | 1,546,137 | 0% | 1% | $1,762,596 |
| Prosight Management, LP | 2.2% | 1,370,233 | -18% | 0.27% | $1,562,066 |
| Peapod Lane Capital LLC | 2.1% | 1,309,013 | +1.6% | 1% | $1,492,275 |
| Woodline Partners LP | 2.1% | 1,296,534 | -22% | 0% | $1,478,049 |
| BlackRock, Inc. | 1.9% | 1,151,214 | +5% | 0% | $1,312,384 |
| Ikarian Capital, LLC | 1.6% | 1,000,000 | 0.19% | $1,140,000 | |
| Eversept Partners, LP | 1.4% | 891,425 | 0% | 0.06% | $1,016,224 |
| MARSHALL WACE, LLP | 1.3% | 835,124 | -16% | 0% | $952,041 |
| Redmile Group, LLC | 1.2% | 772,126 | 0% | 0.06% | $880,224 |
| JPMORGAN CHASE & CO | 1.1% | 681,647 | -21% | 0% | $783,894 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1% | 643,120 | -10% | 0% | $733,157 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.93% | 578,577 | +39% | 0% | $659,954 |
| UBS Group AG | 0.92% | 571,760 | -46% | 0% | $651,806 |
| MILLENNIUM MANAGEMENT LLC | 0.9% | 559,447 | -53% | 0% | $637,770 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.89% | 553,630 | 0% | 0.01% | $631,138 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.87% | 536,081 | +3.6% | 0% | $611,132 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Latest
Q2 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 48,099,455 | $54,832,301 | -$2,274,475 | $1.14 | 84 |
| 2026 Q1 | 49,680,361 | $62,482,903 | +$3,349,912 | $1.26 | 89 |
| 2025 Q4 | 46,690,012 | $57,540,105 | -$7,186,194 | $1.22 | 95 |
| 2025 Q3 | 50,406,732 | $74,592,710 | +$1,536,181 | $1.48 | 97 |
| 2025 Q2 | 51,491,424 | $59,725,484 | -$8,565,167 | $1.16 | 112 |
| 2025 Q1 | 57,869,854 | $78,126,006 | -$216,549,992 | $1.35 | 138 |
| 2024 Q4 | 64,754,179 | $852,599,671 | +$21,507,892 | $13.17 | 158 |
| 2024 Q3 | 63,483,171 | $714,277,363 | -$5,607,911 | $11.21 | 149 |
| 2024 Q2 | 63,896,951 | $686,885,070 | -$18,557,994 | $10.75 | 141 |
| 2024 Q1 | 65,187,064 | $971,256,923 | +$41,504,855 | $14.90 | 133 |
| 2023 Q4 | 62,712,668 | $1,135,768,923 | +$100,850,737 | $18.11 | 133 |
| 2023 Q3 | 60,161,028 | $1,043,150,835 | +$29,447,949 | $17.34 | 134 |
| 2023 Q2 | 58,042,121 | $1,051,734,729 | +$9,423,269 | $18.12 | 141 |
| 2023 Q1 | 56,237,135 | $1,495,380,265 | +$312,862,520 | $26.60 | 143 |
| 2022 Q4 | 44,702,851 | $864,087,630 | -$14,811,927 | $19.33 | 123 |
| 2022 Q3 | 45,386,319 | $948,113,021 | +$327,405,105 | $20.89 | 107 |
| 2022 Q2 | 30,133,558 | $241,439,678 | -$11,245,591 | $8.01 | 81 |
| 2022 Q1 | 31,426,255 | $220,339,413 | +$4,111,275 | $7.01 | 85 |
| 2021 Q4 | 30,850,148 | $416,473,043 | +$5,468,177 | $13.50 | 81 |
| 2021 Q3 | 30,380,086 | $512,798,759 | -$14,863,235 | $16.88 | 75 |
| 2021 Q2 | 30,676,131 | $893,270,740 | -$1,364,693 | $29.12 | 80 |
| 2021 Q1 | 30,719,770 | $1,208,139,215 | +$88,069,181 | $39.33 | 76 |
| 2020 Q4 | 28,511,470 | $647,801,804 | +$7,265,154 | $22.72 | 57 |
| 2020 Q3 | 28,195,401 | $635,735,229 | +$17,040,139 | $22.65 | 53 |
| 2020 Q2 | 26,908,341 | $868,442,000 | +$868,442,000 | $32.46 | 36 |